semaglutide trizepatide Tirzepatide Linked to Better CV Outcomes Than Semaglutide vs. Tirzepatide., It's one

Karahan et al

Increased expression of the FMO3 gene could be a culprit in atherosclerosis and CVD.8 FMO3 may have adverse effects on blood lipids and glucose independently of TMAO formation, although more research is needed.15 Also, in the liver, trimethyllysine (TML), a modified amino acid, can be converted to GBB and then to carnitine and potentially to TMA and TMAO

Semaglutide also stimulates your pancreas to release more insulin when blood sugar rises after meals, then reduces insulin secretion during fasting periods when blood sugar is already normal

The decision to use GLP-1 receptor agonists should be based on their licensed indications (diabetes or obesity management) rather than cholesterol lowering alone, with lipid improvements considered a beneficial additional effect within a comprehensive cardiovascular risk reduction strategy